| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that its common stock continues to trade uninterrupted on the Nasdaq Stock Market under the stock ticker "SLRX."
S&P CapIQ inaccurately characterized the Salarius Pharmaceuticals and Decoy Therapeutics merger and inaccurately stated that the Company had been delisted from the Nasdaq Capital Market. The Company is working to have this inaccurate information corrected. Similar inaccuracies that appeared on Yahoo Finance were corrected earlier this week.
On November 13, 2025, Salarius completed an underwritten public offering raising gross proceeds of $8 million and consummated the previously announced merger with Decoy Therapeutics (Decoy). As of the date of this release, the combined company had pro forma cash of approximately $14 million and approximately 5.9 million shares of common stock outstanding. The company is focused on advancing Decoy's pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing.
During the next 12 months, Decoy expects to advance its lead asset, a pan-coronavirus antiviral, to the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), and to make progress on other programs including a novel broad-acting antiviral to treat flu, COVID-19 and respiratory syncytial virus (RSV), and a peptide drug conjugate targeting GI cancers.
Posted In: SLRX
